Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–14 of 14 results
Advanced filters: Author: Tabitha M. Powledge Clear advanced filters

    • Tabitha M. Powledge
    Special Features
    Bio/Technology
    Volume: 2, P: 214-228

  • For years scientists have dreamed of cleaning up the environment and eliminating pollution by genetic engineering of microorganisms. They have made some progress, but serious technical and regulatory obstacles stand in their way. Because the outlook for profits is not encouraging, industry is showing little enthusiasm for substantial development of microbial pollution control.

    • Tabitha M. Powledge
    Special Features
    Bio/Technology
    Volume: 1, P: 743-755

  • Biogen, perhaps the most international and certainly one of the most successful of the biotech specialist firms, is trying to graduate from a research corporation into a pharmaceutical manufacturer and marketer. Its recent public offering was designed to propel the company into this new stage by expanding its clinical testing program and building production facilities. With only one small-volume product on the market, and facing fierce competition from both the established pharmaceutical multinationals and the research-oriented gene splicing companies, Biogen struggles to position itself for the future.

    • Tabitha M. Powledge
    Special Features
    Bio/Technology
    Volume: 1, P: 398-405

  • Government oversight of genetic engineering in the U.S. is on the verge of shifting its concerns from safety in experimentation to areas such as gene therapy and other uses that affect humans directly. To the relief of industrial observers, this oversight will probably focus on clinical applications rather than the manufacturing of substances. Few similiar signs are apparent elsewhere, but other countries are keeping an eye on U.S. developments. Around the world, the trend toward relaxation of regulation continues.

    • Tabitha M. Powledge
    Special Features
    Bio/Technology
    Volume: 1, P: 322-328